SELLAS Life Sciences (SLS) Operating Expenses (2010 - 2026)

SELLAS Life Sciences (SLS) has reported Operating Expenses for 17 consecutive years, with $9.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Operating Expenses rose 52.6% year-over-year to $9.3 million; the TTM figure through Mar 2026 stood at $31.5 million (up 12.65% YoY), while the FY2025 annual figure was $28.3 million, down 10.28% from the prior year.
• Operating Expenses grew to $9.3 million in Q1 2026 per SLS's latest filing, from $8.3 million in the prior quarter.
• Across five years, Operating Expenses topped out at $17.7 million in Q1 2022 and bottomed at $6.1 million in Q1 2025.
• Historically, Operating Expenses has averaged $8.8 million across 5 years, with a median of $8.3 million in 2025.
• Annual changes were most pronounced in 2022 — Operating Expenses soared 123.22% — and 2025, when it tumbled 37.14%.
• SELLAS Life Sciences' Operating Expenses stood at $9.4 million in 2022, then slipped by 13.43% to $8.2 million in 2023, then slipped by 15.4% to $6.9 million in 2024, then rose by 19.33% to $8.3 million in 2025, then gained by 12.08% to $9.3 million in 2026.
• Business Quant data shows SLS's Operating Expenses at $9.3 million in Q1 2026, $8.3 million in Q4 2025, and $7.1 million in Q3 2025.